Under construction – not a live service
Sign in
Taking people in CzechiaNo phase

Urine Fetuin A as a Predictor of Kidney Decline in High Blood Pressure

Observes whether a urine protein predicts kidney decline in adults with high blood pressure.

Plain-language title generated from the registry record
Registry title: Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients

Key facts

Where
Ostrava, CzechiaSee the site

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with high blood pressure who take at least one blood pressure medicine. It studies whether a urine marker, Fetuin A, can predict worsening kidney function.

Age
18 to 100 years
Sex
All sexes can join.
Disease stage
Arterial hypertension (high blood pressure) treated with at least one blood pressure medicine. High blood pressure that is out of control cannot be included.
Earlier treatment
Must take at least one blood pressure medicine.

Main reasons for not taking part

  • Any type of diabetes
  • Uncontrolled high blood pressure (office blood pressure above 180/110 mmHg)
  • Kidney replacement treatment
  • Rheumatoid disease (for example rheumatoid arthritis or lupus) or positive ANA/ENA screening
  • Acute infection (CRP above 50 mg/l)

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Source: NCT05963126, who can take part

Where in Czechia

  • University Hospital Ostrava, - Department of Internal Medicine and CardiologyOstrava, CzechiaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital Ostrava
Trial code
NCT05963126
Record updated
27 July 2023
Original description
Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. Modified human urine Fetuin A (urine Fetuin A) with specific modification in urine (Fetuin A) can earlier predict the progression of kidney disease in patients with diabetes. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.Read full original descriptionShow less

Modified Urine Fetuin A as a Predictor of Deterioration of Renal Function in Patients With Resistant and Non-resistant Hypertension

Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. Modified human urine Fetuin A (urine Fetuin A) with specific modification in urine (Fetuin A) can earlier predict the progression of kidney disease in patients with diabetes. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.

Inclusion: Arterial hypertension treated by at least one antihypertensive agent.

Exclusion: Patient with renal replacement therapy; Decompensated arterial hypertension defined as office blood pressure >180/110 mmHg or on Ambulatory Blood Pressure Monitoring (ABPM); Present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, Inflammatory Bowel Disease, etc.), positivity of antinuclear antibody (ANA) / extractable nuclear antigen (ENA) screening; Acute infection defined as C-Reactive Protein (CRP) >50 mg/l; Terminal incurable illness; Diabetes mellitus of any type, defined as fasting glucose >7,0 mmol/l or any glycemia >11,0 mmol/l, or HbA1c>48 mmol/mol; Severe impairment of liver function defined as cirrhosis, Alanine Transaminase or ASpartate Transferase (ALT or AST) >10 µkat/l.

ClinicalTrials.gov NCT05963126